1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (813) 745-4384
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have free access to this content
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
Article first published online: 17 JUN 2009
DOI: 10.1002/cncr.24473
Copyright © 2009 American Cancer Society
Additional Information
How to Cite
Weber, J. S., Zarour, H., Redman, B., Trefzer, U., O'Day, S., van den Eertwegh, A. J. M., Marshall, E. and Wagner, S. (2009), Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer, 115: 3944–3954. doi: 10.1002/cncr.24473
Publication History
- Issue published online: 20 AUG 2009
- Article first published online: 17 JUN 2009
- Manuscript Accepted: 15 DEC 2008
- Manuscript Revised: 4 DEC 2008
- Manuscript Received: 3 SEP 2008
References
- 1, . Pathogen recognition with TLRs. Curr Opin Immunol. 2005; 17: 338-344.
- 2, . Innate immune recognition of viral infection. Nat Immunol. 2006; 7: 131-136.
- 3, , . A human homologue of Drosophila Toll signals activation of adaptive immunity. Nature. 1997; 388: 394-397.
- 4. Mammalian Toll-like receptors. Curr Opin Immunol. 2003; 15: 5-11.
- 5, , , et al. LPS activates NFκB through TLR4 in endothelial cells. J Biol Chem. 2000; 275: 11058-11063.
- 6, , , , , . Evidence of TLRs on human platelets. Immunol Cell Biol. 2005; 83: 196-198.Direct Link:
- 7. Alerting DCs to pathogens: the importance of TLR signaling of stromal cells. Proc Natl Acad Sci U S A. 2004; 101: 16083-16084.
- 8. Signaling in B cells via TLRs. Curr Opin Immunol. 2005; 17: 230-236.
- 9, , , et al. TLR8-mediated reversal of regulatory T cell function. Science. 2005; 309: 1380-1384.
- 10. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20: 709-760.
- 11, , , et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001; 167: 4878-4886.
- 12, , , . Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 1999; 59: 5429-5432.
- 13, , , . Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res. 2000; 6: 2469-2473.
- 14, , , . CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003; 9: 3105-3114.
- 15, , , et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 2004; 64: 5074-5077.
- 16, , , et al. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer. 2004; 40: 1275-1281.
- 17, , , et al. Phase II trial of a toll-like receptor 9 activating oligodeoxynucleotide in patients with metastatic melanoma. J Clin Oncol. 2006; 24: 5716-5724.
- 18, , . Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003; 63: 3281-3288.
- 19, , , et al. CpG motifs are efficient adjuvants for cancer vaccines. J Invest Derm. 2004; 1213: 371-379.
- 20, , , et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005; 115: 739-746.
- 21, , . Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood. 2001; 98: 1217-1225.
- 22, , . New approaches to the systemic treatment of melanoma. Cancer Treat Rev. 1999; 25: 259-270.
- 23, , , et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol. 2006; 8: 60-66.
- 24, , , , , . Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998; 16: 1743-1751.
- 25, , , et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3979-3986.
- 26, , , et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine [abstract]. J Clin Oncol. 2008; 26( suppl):136s. Abstract 9022.
- 27, , , . Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007; 25: 5426-5434.
- 28. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008; 27: 161-167.